Genetic engineering: Genentech claims factor VIII

FACTOR V AND VIII INHIBITOR IN PATIENTS WITH COMBINED FACTOR V AND VIII DEFICIENCY

Patients with coagulation factor(s) deficiency who use coagulation therapy are susceptible to forming inhibitors against coagulation factor(s). In this survey we detected factor V and VIII inhibitor in ten patients with combined deficiency of factors V and VIII from north east of Iran (Khorassan province). It was revealed in our survey that eight patients had both factor V and factor VIII i...

Engineering regulatory T cells against factor VIII inhibitors.

Genentech, Inc

How did it start? It began in 1976 with a meeting over a glass of beer between Bob Swanson, then a bright young venture capitalist, and Herb Boyer (UCSF), who with Stan Cohen (Stanford) had just performed some of the key experiments of recombinant DNA technology. The meeting is now immortalized in a brass statue in the new Founders’ Research Center. Genentech was founded later that year, and cl...

Combined Factor V and VIII Deficiency

This review summarizes current data on the pathomechanisms and new genetic findings of combined factor V and VIII deficiency (CF5F8D). Congenital haemorrhagic disorders characterized by deficiency of two clotting factors comprise an interesting group. Among dual coagulation disorders, CF5F8D is the most common type. For the first time combined factor V and VIII deficiency (F5F8D) was reported b...

FIXing factor VIII inhibitors.

2007;25(11):1315-1321. 6. Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008;13(6):483-495. 7. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 20...